| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2023-02-14 | CITADEL ADVISORS LLC | Oncorus, Inc. | - | 7.2% | EDGAR |
| SC 13G/A | 2023-02-13 | CHI Advisors LLC | Oncorus, Inc. | 2,367,436 | 9.1% | EDGAR |
| SC 13G/A | 2023-02-02 | Arkin Moshe | Oncorus, Inc. | 1,067,093 | 4.1% | EDGAR |
| SC 13D/A | 2023-01-19 | Flynn James E | Oncorus, Inc. | 451,940 | 1.7% | EDGAR |
| SC 13D/A | 2023-01-17 | Flynn James E | Oncorus, Inc. | 704,097 | 2.7% | EDGAR |
| SC 13D/A | 2023-01-03 | Flynn James E | Oncorus, Inc. | 1,129,095 | 4.4% | EDGAR |
| SC 13D/A | 2022-12-22 | Flynn James E | Oncorus, Inc. | 1,338,669 | 5.2% | EDGAR |
| SC 13G | 2022-11-01 | K2 HealthVentures Equity Trust LLC | Oncorus, Inc. | 2,593,767 | 9.1% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | Oncorus, Inc. | 278,740 | 1.1% | EDGAR |
| SC 13G/A | 2022-02-15 | PERCEPTIVE ADVISORS LLC | Oncorus, Inc. | 999,812 | 3.9% | EDGAR |
| SC 13G/A | 2022-02-14 | CITADEL ADVISORS LLC | Oncorus, Inc. | - | 7.3% | EDGAR |
| SC 13G/A | 2022-02-11 | CHI Advisors LLC | Oncorus, Inc. | 2,106,903 | 8.2% | EDGAR |
| SC 13G | 2022-02-04 | BlackRock Inc. | Oncorus, Inc. | 1,354,009 | 5.2% | EDGAR |
| SC 13G | 2021-12-02 | Arkin Moshe | Oncorus, Inc. | 1,067,093 | 4.1% | EDGAR |
| SC 13G | 2021-03-02 | CHI Advisors LLC | Oncorus, Inc. | 1,679,906 | 6.6% | EDGAR |
| SC 13G/A | 2021-02-16 | CITADEL ADVISORS LLC | Oncorus, Inc. | - | 8.2% | EDGAR |
| SC 13G | 2021-02-16 | PERCEPTIVE ADVISORS LLC | Oncorus, Inc. | 1,989,987 | 7.7% | EDGAR |
| SC 13D | 2020-10-21 | MPM BioVentures 2014, L.P. | Oncorus, Inc. | 2,179,719 | 10.0% | EDGAR |
| SC 13D | 2020-10-16 | Flynn James E | Oncorus, Inc. | 1,268,344 | 5.8% | EDGAR |
| SC 13G | 2020-10-13 | CITADEL ADVISORS LLC | Oncorus, Inc. | - | 8.5% | EDGAR |